Active Biotech, Ipsen Announced Half Plan recruitment in Tasquinimod

Active Biotech and Ipsen introduced that in fact recruitment to the global, essential, randomized, double-blind, placebo-controlled phase III evaluation of tasquinimod in affected individuals along with metastatic castrate-resistant prostate cancer (CRPC) has met an inclusion of 600 affected individuals, 50 % the planned accumulation. This approach prompts€10 million milestone compensation from Ipsen to Active Biotech.

The purpose of the Phase III study would be to make sure tasquinimod's efficacy on metastatic CRPC within the prechemotherapy setting, by using radiological progression free survival (PFS) as the main endpoint and overall survival (OS) as secondary endpoint. The research will include about 1,200 affected individuals in more than 250 centers. Recruitment is proceeding in accordance with plan with best line outcome anticipated by the end of 2013.